DVAX — Dynavax Technologies Income Statement
0.000.00%
Last trade - 00:00- $1.32bn
- $834.51m
- $277.25m
- 89
- 29
- 92
- 81
Annual income statement for Dynavax Technologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 46.6 | 439 | 723 | 232 | 277 |
| Cost of Revenue | |||||
| Gross Profit | 32.6 | 266 | 461 | 182 | 228 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 115 | 310 | 439 | 269 | 281 |
| Operating Profit | -68.4 | 129 | 284 | -37 | -4.12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -75.2 | 77.5 | 294 | -4.37 | 30.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -75.2 | 76.7 | 293 | -6.39 | 27.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -75.2 | 76.7 | 293 | -6.39 | 27.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -75.2 | 72.1 | 296 | -6.39 | 27.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.792 | 0.588 | 1.97 | -0.035 | 0.205 |